Dr. André Uddin

Research Capital Corporation

Image: Dr. André Uddin

Andre Uddin is managing director, healthcare research at Mackie Research. Uddin has over 20 years of global experience in the investment, biotechnology and pharmaceutical industries, most recently as strategic advisor and consultant to a number of leading TSX and LSE companies. He was also Vice-President of Strategic Development for a NASDAQ-listed biopharmaceutical company. Uddin began his career in the brokerage community, where he was a top-ranked analyst specializing in coverage of the Canadian biotechnology, pharmaceutical and medical device sectors at National Bank Financial, Research Capital and Merrill Lynch Canada. Uddin holds an Honours Bachelor of Science in Biochemistry from the University of Toronto, and a Ph.D in Biological Chemistry from McGill University. Uddin's bio-organic research has been widely published in many scientific journals, including the Journal of American Chemical Society, Biochemistry and Nucleic Acid Research.

Recent Quotes

"Positive Phase 2a data were achieved with AGN's ifenprodil."

— Dr. André Uddin, Research Capital Corporation (11/30/22)
more >

"It would be logical for AGN to develop ifenprodil for two indications."

— Dr. André Uddin, Research Capital Corporation (7/28/22)
more >

"In the Phase 2a trial in IPF, AGN's ifenprodil hit its endpoint."

— Dr. André Uddin, Research Capital Corporation (7/18/22)
more >

"AGN's current valuation is favorable from a risk-reward standpoint."

— Dr. André Uddin, Research Capital Corporation (1/28/22)
more >

"AGN's risk/reward profile is attractive."

— Dr. André Uddin, Research Capital Corporation (12/6/21)
more >

"AGN is switching focus to the IPF/chronic cough indication."

— Dr. André Uddin, Research Capital Corporation (8/4/21)
more >

"AGN requested a meeting with the FDA to discuss advancing ifenprodil."

— Dr. André Uddin, Research Capital Corporation (5/10/21)
more >

"Final results from AGN's Phase 2b COVID-19 trial are expected soon."

— Dr. André Uddin, Research Capital Corporation (3/1/21)
more >



Due to permission requirements, not all quotes are shown.